Studies on animal and human subjects have shown that greatly increasing the amount of linseed (also known as flaxseed) oil (rich in the n-3 polyunsaturated fatty acid (PUFA) a-linolenic acid (ALNA)) or fish oil (FO; rich in the long-chain n-3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) in the diet can decrease a number of markers of immune function. The immunological effects of more modest doses of n-3 PUFA in human subjects are unclear, dose-response relationships between n-3 PUFA supply and immune function have not been established and whether ALNA has the same effects as its long-chain derivatives is not known. Therefore, the objective of the present study was to determine the effect of enriching the diet with different doses of FO or with a modest dose of ALNA on a range of functional responses of human monocytes and lymphocytes. In a randomised, placebo-controlled, doubleblind, parallel study, forty healthy males aged 18 -39 years were randomised to receive placebo or 3·5 g ALNA/d or 0·44, 0·94 or 1·9 g (EPAþDHA)/d in capsules for 12 weeks. The EPA:DHA ratio in the FO used was 1·0:2·5. ALNA supplementation increased the proportion of EPA but not DHA in plasma phospholipids. FO supplementation decreased the proportions of linoleic acid and arachidonic acid and increased the proportions of EPA and DHA in plasma phospholipids. The interventions did not alter circulating mononuclear cell subsets or the production of tumour necrosis factor-a, interleukin (IL) 1b, IL-2, IL-4, IL-10 or interferon-g by stimulated mononuclear cells. There was little effect of the interventions on lymphocyte proliferation. The two higher doses of FO resulted in a significant decrease in IL-6 production by stimulated mononuclear cells. It is concluded that, with the exception of IL-6 production, a modest increase in intake of either ALNA or EPAþDHA does not influence the functional activity of mononuclear cells. The threshold of EPAþDHA intake that results in decreased IL-6 production is between 0·44 and 0·94 g/d.
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Monocytes and lymphocytes form part of the immune response that is responsible for host defence against invading pathogens. Bacterial cell wall components such as lipopolysaccharide (LPS) stimulate the production by monocytes of cytokines, such as tumour necrosis factor (TNF) and interleukins (IL) 1 and 6. These inflammatory cytokines provide one link between the innate and specific immune systems as they can stimulate T and B lymphocytes (Abbas et al. 1994) . The interaction between these cell types also involves cell surface proteins, such as intercellular adhesion molecule (ICAM)-1 (CD54) and CD11b. When T lymphocytes are activated, they secrete cytokines and ultimately enter the cell cycle and divide (Abbas et al. 1994) . This proliferation of lymphocytes leads to an increase in the number of antigen-specific lymphocytes. In cell culture, the stimulation and subsequent proliferation of T lymphocytes can be achieved by mitogens such as concanavalin A (ConA) (Licastro et al. 1993) . T lymphocytes are classified into helper T cells, distinguished by the presence of the molecule CD4 on their surface, and cytotoxic T cells, distinguished by the presence of CD8 on their surface. T lymphocytes can also be sub-divided functionally according to the pattern of cytokines they produce. Type-1 helper T lymphocytes produce IL-2 and interferon (IFN)-g, while type-2 helper T lymphocytes produce IL-4, -5 and -10 (Abbas et al. 1994) , although T cells are not the only sources of these cytokines. Over the last 10 years there has been increasing interest in the effects of n-3 polyunsaturated fatty acids (PUFA) on human immune function (for reviews, see Calder, 2001a,b) . Studies have been short and have focused on the effects of the longer-chain n-3 PUFA eicosapentaenoic acid (EPA; 20 : 5n-3) and docosahexaenoic acid (DHA; found in fish oil (FO), rather than on those of the precursor a-linolenic acid (ALNA; 18 : 3n-3). FO, providing . 2·4 g (EPA + DHA)/d decreased the production of TNF-a, IL-1b and IL-6 by LPS-stimulated mononuclear cells (Endres et al. 1989; Meydani et al. 1991b; Gallai et al. 1993; Caughey et al. 1996) , decreased lymphocyte proliferation (Meydani et al. 1991b; Virella et al. 1991; Endres et al. 1993; Gallai et al. 1993) and decreased the production of IL-2 (Meydani et al. 1991b Molvig et al. 1991; Virella et al. 1991; Endres et al. 1993; Gallai et al. 1993) and IFN-g (Gallai et al. 1993) . Although some studies using lower doses of EPA + DHA revealed limited immunological impact (Cooper et al. 1993; Schmidt et al. 1996; Blok et al. 1997; Thies et al. 2001a,b) , there has been no attempt to define the doseresponse relationship between provision of EPA + DHA and immune function. Only a few studies have investigated the immunological effects of ALNA in human subjects. Increasing the amount of ALNA in the diet to about 14 g/d for 4 weeks resulted in a significant decrease in TNF-a and IL-1b production by LPS-stimulated mononuclear cells (Caughey et al. 1996) , while 18 g ALNA/d for 8 weeks resulted in a significant decrease in ConAstimulated lymphocyte proliferation (Kelley et al. 1991) . There has been only one investigation of the influence of a modest dose of ALNA (2 g/d) on mononuclear cell function (Thies et al. 2001a,b) . In addition, apart from the studies of Thies et al. (2001a,b) , using a modest dose of ALNA, and of Caughey et al. (1996) , using a very high dose of ALNA, there has been no direct comparison of the immunological effects of ALNA and EPA + DHA. Most often, the finding that n-3 PUFA diminish inflammatory and immune cell functions is interpreted in a favourable way, with the conclusion that they are antiinflammatory and so will be beneficial to health (Calder, 2002) . However, since these cells are the cellular components of the immune system, a reduction in their activities could compromise host defence. There are recommendations to increase the intake of n-3 PUFA in adults because of their beneficial health effects (British Nutrition Foundation, 1992 de Decekere et al. 1998) . However, the studies described earlier suggest that potentially detrimental immunological effects can occur at high ALNA and EPA + DHA intakes. It is important to understand more about the immunological effects of lower doses of n-3 PUFA, to identify doseresponse relationships, and to determine whether ALNA and its long-chain derivatives have similar effects. Therefore, the current study compared the immunological effects of supplementation of the diet of healthy subjects with a modest dose of ALNA or with three doses of EPAþ DHA.
Subjects and methods

Materials
PBS tablets were obtained from Unipath Ltd, Basingstoke, Hants., UK. Histopaque, 4-(2-hydroxyethly)-1-piperazineethanesulfonic acid-buffered Roswell Park Memorial Institute medium, glutamine, antibiotics (penicillin and streptomycin), ConA, Escherichia coli 0111:B4, LPS, boron trifluoride, formaldehyde, solvents and standard chemicals were purchased from Sigma Chemical Co. Ltd (Poole, Dorset, UK). Fluorescein isothiocyanate-labelled mouse anti-human CD3, CD14 and CD19 and R-phycoerythrin-labelled mouse anti-human CD4, CD8, CD11b, CD16 and CD54 were purchased from Serotec Ltd (Kidlington, Oxon., UK). [ 3 H]Thymidine was purchased from Amersham International Ltd (Amersham, Bucks., UK). Cytokine EASIAe ELISA kits were obtained from BioSource (Nivelles, Belgium).
Subjects and study design
Ethical permission for all procedures involving human volunteers was obtained from the Southampton and South West Hampshire Joint Ethics Committee. Healthy adults aged 18-39 years were invited to participate in the study. All volunteers completed a health and lifestyle questionnaire prior to entering the study, and doctor's consent for inclusion into the study was obtained. Volunteers were excluded if they were taking any prescribed medication, were vegetarian, consumed FO, evening primrose oil or vitamin supplements, smoked more than ten cigarettes per d, drank more than ten units of alcohol per week, had a BMI. 32 kg/m 2 , or consumed more than two portions of oily fish per week. Blood pressure was measured in a sitting position using a commercially available monitor. Forty subjects were recruited to the study and all completed it. Plasma triacylglycerol concentrations were measured using a commercially available colorimetric assay (procedure no. 2337; Sigma Chemical Co.). The characteristics of the subjects are given in Table 1 ; mean age, BMI, blood pressure and fasting plasma triacylglycerol concentration did not differ among the treatment groups at study entry.
Subjects were randomly allocated in a double-blind fashion to one of five intervention groups (n 8 per group). Each group consumed nine 1 g capsules per d for 12 weeks. This period was chosen because previous studies have demonstrated significant effects of n-3 PUFA supplementation on proliferation and cytokine production by mononuclear cells by 12 weeks (Endres et al. 1989 (Endres et al. , 1993 Meydani et al. 1991b; Molvig et al. 1991; Gallai et al. 1993; Caughey et al. 1996; Kelley et al. 1998 Kelley et al. , 1999 Thies et al. 2001b) . The capsules used were generously provided by Scotia Pharmaceuticals Ltd, Carlisle, Cumbria, UK. The placebo group consumed capsules containing palm oil -soyabean oil (80:20, w/w); this mix has a fatty acid composition that closely resembles that of the average UK diet (British Nutrition Foundation 1992 . The ALNA group consumed capsules containing linseed (also known as flaxseed) oil, which provided 3·5 g ALNA/d. The other three groups consumed blends of the placebo and tuna oils providing 0·44, 0·94 and 1·9 g (EPA + DHA)/d; these are referred to as low-, mediumand high-FO groups. The EPA:DHA ratio in the tuna oil was approximately 1·0:2·5. The fatty acid compositions of the capsules are shown in Table 2 . The levels of EPA + DHA used were selected to represent an intake that could be achieved through supplementation of the habitual diet with one typical FO capsule per d (approximately 0·4 g/d), the intake of long-chain n-3 PUFA recommended by the British Nutrition Foundation (1999) (approximately 1 g/d), and the intake of long-chain n-3 PUFA provided by one oily fish meal/d (approximately 2 g/d; British Nutrition Foundation, 1999). The metabolic equivalence of ALNA:EPA has been assumed to be approximately 7 (Sanders & Roshanai, 1983; Indu & Ghafoorunissa, 1992; Emken et al. 1994) . Thus, the level of ALNA used in the current study (3·5 g/d) was selected to match the intake of EPA in the high-FO group, assuming a metabolic equivalence of approximately 7 and taking into account habitual intake of these two fatty acids. Each capsule contained 1 mg a-tocopherol. Capsules were provided to subjects in tubs, each containing 300 capsules. Tubs were returned every 4 weeks and weighed to assess compliance; subjects were unaware of this procedure. Mean compliance was . 90 % across all treatment groups and was not significantly different among groups. All treatment groups completed the study in parallel. The study ran from January 1998 (mid-winter) to April 1998 (early spring). Blood was collected immediately prior to beginning the interventions and at 12 weeks. Heparinised vacutainer tubes were used for blood collection, which was between 08·00 and 10·00 h after a fast of^10 h.
Analysis of habitual nutrient intakes
Subjects completed two 5 d food diaries separated by 8 weeks. Habitual nutrient intakes were determined using FOODBASE, version 1.3 (Institute of Brain Chemistry, London, UK).
Analysis of plasma thiobarbituric acid-reactive substances and a-tocopherol concentrations Plasma thiobarbituric acid-reactive substances (TBARS) concentrations were measured by incubating 100 ml plasma with 1·2 ml thiobarbituric acid (3·35 g/l TCA (100 g/l)) for 15 min at 958C and recording the absorbance at 535 nm after cooling; TBARS concentrations were calculated using an extinction coefficient of 1·56 £ 10 4 (mmol/ l) 21 /mm. Prior to determination of a-tocopherol concentrations, plasma (100 ml) was vortexed with methanol and diethyl ether, then centrifuged for 5 min at 3000 g. The upper layer was evaporated to dryness under N 2 and then reconstituted with methanol; the concentration of a-tocopherol was then analysed by normal phase HPLC using a Varian 9095 delivery system, Varian 9050 u.v. 0·16  0·4  0·03  5·1  0·39  4·9  0·37  6·0  0·46  Palmitic acid  34·9  2·67  7·0  0·53  30·3  2·32  29·6  2·26  22·8  1·74  Palmitoleic acid  2·0  0·15  0·2  0·01  3·3  0·26  4·3  0·33  5·3  0·40  Stearic acid  3·7  0·29  6·5  0·49  4·5  0·34  5·0  0·38  6·7  0·53  Oleic acid  33·8  2·58  18·9  1·45  27·3  2·09  25·2  1·92  15·5  1·19  Linoleic acid  18·9  1·45  16·9  1·29  14·4  1·11  12·0  0·91  2·4  0·18  ALNA  1·8  0·14  45·9  3·51  2·3  0·18  2·1  0·16  1·6  0·13  ARA  0  0  1·7  0·13  0  0  2·2  0·17  2·3  0·18  EPA  0  0  0  0  1·9  0·15  3·3  0·27  6·4  0·49  DHA  0  0  0  0  3·7  0·29  8·7  0·67  18·5  1·41 ALNA, a-linolenic acid; FO, fish oil; ARA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
n-3 Fatty acids and mononuclear cell functionn-3 Fatty acids and mononuclear cell functiondetector and Varian 9012 pump on an Apex II 4·6 m £ 150 mm analytical column, with a flow rate of 2·5 ml/min and mobile phase consisting of water -methanol (4·5:95·5, v/v) (Varian, Palo Alto, CA, USA). HPLC analysis was performed by the Chemical Pathology Laboratory of the Southampton University Hospitals NHS Trust (Southampton General Hospital, Southampton, Hants., UK).
Analysis of plasma phospholipid fatty acid composition
Lipid was extracted from plasma with chloroform -methanol (2:1, v/v) and phospholipids isolated by TLC using hexane -diethyl ether -acetic acid (90:30:1, by vol.) as the elution phase. Fatty acid methyl esters were prepared by incubation with 140 g boron trifluoride/l methanol at 808C for 60 min. Fatty acid methyl esters were isolated by solvent extraction, dried and separated in a HewlettPackard 6890 GC (Hewlett Packard, Avondale, PA, USA) fitted with a 30 m £ 0·32 mm BPX70 capillary column, film thickness 0·25 mm. The carrier gas was He at 1·0 ml/min and the split -splitless injector was used with a split: splitless ratio of 20:1. Injector and detector temperatures were 2758C. The column oven temperature was maintained at 1708C for 12 min after sample injection and was programmed to then increase from 170 to 2108C at 58C/min before being maintained at 2108C for 15 min. The separation was recorded with HP GC Chem Station software (Hewlett Packard). Fatty acid methyl esters were identified by comparison with standards run previously.
Preparation of peripheral blood mononuclear cells
Blood was layered onto Histopaque (density 1·077 g/l; blood -Histopaque 1:1, v/v) and centrifuged for 15 min at 800 g at 208C. The cells (termed peripheral blood mononuclear cells, PBMC) were collected from the interphase and washed once with Roswell Park Medical Institute medium containing 2 mM-glutamine and antibiotics (penicillin and streptomycin) (culture medium). The cells were then resuspended in 4 ml culture medium and layered onto 4 ml Histopaque. They were centrifuged again to achieve a lower degree of erythrocyte contamination, washed with culture medium and finally resuspended and counted on a Coulter Z1 Cell Counter (Coulter Electronics, Luton, Essex, UK).
Analysis of peripheral blood mononuclear cells subsets
Whole blood (100 ml) was incubated with various combinations of fluorescently labelled monoclonal antibodies (10 ml of each antibody) for 30 min at 48C. Monoclonal antibody combinations used were anti-CD3/anti-CD4 (to distinguish T lymphocytes as CD3 + and T helper lymphocytes as CD3 (CD54) on B lymphocytes), anti-CD19/anti-CD11b (to distinguish CD11b expressing B lymphocytes), anti-CD14/ anti-CD54 (to distinguish monocytes as CD14 + and to determine the expression of ICAM-1 on monocytes) and anti-CD14/anti-CD11b (to distinguish CD11b expressing monocytes). Erythrocytes were then lysed using 2 ml lysing solution (3·7 ml formaldehyde, 4·5 ml diethylene glycol, 1·75 ml 0·2 M-Tris made up to 1 litre with distilled water) and leucocytes washed and then fixed with 0·2 ml fixing solution (20 ml formaldehyde/l PBS). Fixed leucocytes were analysed in a Becton Dickinson FACSCalibur flow cytometer (Becton Dickinson, Oxford, Oxon, UK). Fluorescence data were collected on 5000 cells. Lymphocytes and monocytes were identified by forward and side scatter properties. Data were analysed using Cellquest software (Becton Dickinson, Oxford, Oxon, UK).
Measurement of lymphocyte proliferation peripheral blood mononuclear cell cultures
PBMC ð2 £ 10 5 Þ were cultured at 378C in culture medium supplemented with autologous plasma (50 ml/l) and ConA at final concentrations of 7·5, 15·0, 25·0, 50·0 and 75·0 mg/ ml; the final volume of the culture was 200 ml and all cultures were performed in triplicate. Proliferation was measured as the incorporation of [ 3 H]thymidine over the final 18 h of a 66 h culture period. Thymidine incorporation values for the triplicate cultures were averaged (CV , 10 % and usually , 5 %). Results are expressed as thymidine incorporation (cpm) per well.
Measurement of the production of cytokines by peripheral blood mononuclear cell cultures PBMC ð2 £ 10 6 Þ were cultured at 378C for 24 h in culture medium, supplemented with autologous plasma (50 ml/l) and either ConA (25 mg/ml) or LPS (15 mg/ml); the final culture volume was 2 ml. Preliminary studies indicated that these concentrations of stimulants gave rise to the maximal concentrations of the cytokines under study and that the concentrations of all cytokines measured were maximal at 24 h of culture. At the end of the incubation, the plates were centrifuged and the culture medium collected and frozen in portions. The concentrations of cytokines were measured by specific EASIAe ELISA kits (BioSource). TNF-a, IL-1b and IL-6 were measured in the supernatant fractions of cells stimulated with LPS, and IL-2, IFN-g, IL-4 and IL-10 were measured in the supernatant fractions of cells stimulated with ConA. Limits of detection for these assays were 3 pg/ml (TNFa), 2 pg/ml (IL-1b, IL-6, IL-4), 1 pg/ml (IL-10), 0·1 U/ml (IL-2) and 0·03 IU/ml (IFN-g) (data supplied by the manufacturer of the kits). The inter-and intra-assay CV were , 10 % for all cytokine ELISA.
Statistical analysis
Sample size (i.e. number of subjects per treatment group) was calculated on the basis of measurements made previously in this laboratory using the same methods as those used in this study and of existing results from the literature that reported significant effects of long chain n-3 PUFA supplementation on lymphocyte proliferation and cytokine production (Endres et al. 1989 (Endres et al. , 1993 Meydani et al. 1991b; Molvig et al. 1991; Kelley et al. 1998 Kelley et al. , 1999 Thies et al. 2001b) . It was determined that a sample size of eight would detect a difference in lymphocyte proliferation and cytokine production of . 25 % at P, 0·05 with 80 % power.
Data for each treatment group at each time point were tested for normality using the Kolmogorov -Smirnov test. All data were normally distributed and so are presented as mean values with their standard errors. One-way ANOVA was used to determine differences among treatment groups at baseline (weeks 0) and at the end of supplementation (weeks 12). Student's paired t test was used to determine differences within each treatment group across time. Bonferroni's correction for multiple comparisons was used in all statistical analyses. All statistical tests were performed using SPSS, version 10.0 (SPSS Inc., Chicago, IL, USA) and a value of P, 0·05 was taken to indicate statistical significance.
Results
Habitual nutrient intakes
Habitual nutrient intakes determined from two separate 5 d food diaries completed 8 weeks apart did not differ significantly (paired Student's t test) and so the data were averaged. There were no significant differences among treatment groups with respect to habitual intakes of total energy (10·6 (SEM 0·4) MJ/d for all subjects (n 40)) and energy from fat, carbohydrate and protein (33·6 (SEM 0·9), 45·5 (SEM 0·8) and 14·8 (SEM 0·3) % respectively) or of a-tocopherol (9 (SEM 1) mg/d). Habitual intakes of individual fatty acids did not differ among the treatment groups; results for all subjects combined are shown in Table 3 . Likewise, habitual intakes of total saturated fatty acids, total monounsaturated fatty acids, total PUFA, total n-6 PUFA and total n-3 PUFA did not differ among treatment groups (results not shown).
Fatty acid intakes during treatment
Intakes of individual fatty acids during the period of treatment with the supplements were calculated by adding habitual intakes to intakes due to the supplements (Table 3) . Although intakes of palmitic (16 : 0), palmitoleic (16 : 1n-7), oleic (18 : 1n-9) and linoleic (18 : 2n-6) acids were increased slightly in at least some treatment groups during supplementation, they were not significantly different from habitual intakes. Furthermore, during supplementation intakes of these fatty acids were not different among the treatment groups (Table 3) . In contrast, supplementation affected the intakes of ALNA, arachidonic acid (ARA; 20 : 4n-6), EPA and DHA, such that there were significant differences in the intakes of these fatty acids among the different treatment groups (Table 3) Plasma thiobarbituric acid-reactive substances and a-tocopherol concentrations Plasma TBARS concentration did not differ among the treatment groups at baseline (5·12 (SEM 0·16) mmol/l, n 40) or at the end of supplementation (results not shown). Plasma a-tocopherol concentration did not differ among the treatment groups at baseline (15·9 (SEM 0·6) mmol/l, n 40). Plasma a-tocopherol concentration increased significantly in all groups during treatment (P, 0·05 v. baseline; paired Student's t test). However, there was no difference in plasma a-tocopherol concentration among treatment groups at the end of supplementation (22·0 (SEM 1·4) mmol/l, n 40).
Fatty acid composition of plasma phospholipids
The fatty acid composition of plasma phospholipids did not differ among the treatment groups at baseline (Table 4) , and was not affected by the placebo treatment (Table 4) . None of the treatments significantly altered the proportions of palmitic (approximately 30 g/100 g total fatty acids), stearic (approximately 15 g/100 g total fatty acids) or oleic (approximately 12 g/100 g total fatty acids) acids in Myristic acid  3·30  0·20  3·39  0·40  3·65  0·45  3·42  0·60  3·69  0·30  3·85  0·56  Palmitic acid  16·15  0·69  18·42  1·49  16·94  1·17  19·23  2·35  18·12  1·22  17·59  1·32  Palmitoleic acid  1·15  0·05  1·19  0·14  1·28  0·09  1·37  0·15  1·53  0·09  1·54  0·11  Stearic acid  7·41  0·36  6·81  0·67  8·04  0·49  8·25  1·31  7·95  0·73  8·02  0·50  Oleic acid  22·77  0·05  24·01  1·84  23·24  2·50  27·19  2·83  24·58  1·73  23·81  1·81  Linoleic acid  12·63  0·76  13·34  1·52  14·20  1·58  16·09  1·45  13·25  1·71  11·29  2·10  ALNA  1·24  0·06 Mean values within a row with unlike superscript letters were significantly different (one-way ANOVA; P, 0·001). * For details of subjects, supplements and procedures, see Tables 1 and 2 , and p. 680.
n-3 Fatty acids and mononuclear cell functionn-3 Fatty acids and mononuclear cell functionplasma phospholipids. Consumption of ALNA did not result in significant appearance of ALNA in plasma phospholipids. However, ALNA consumption increased the proportion of EPA (by 60 %) such that the proportion was significantly (P, 0·05) greater than at baseline and significantly (P, 0·05) higher than that in the placebo group (Table 4) . ALNA consumption did not alter the proportion of DHA in plasma phospholipids (Table 4) . Consumption of FO resulted in a significant (P, 0·05) decrease in the proportion of ARA in plasma phospholipids (maximum 25 % decrease), although this did not appear to relate to the dose of EPA + DHA provided (Table 4 ). The medium and high doses of FO also resulted in a significant (P, 0·05) decrease (about 15 %) in the proportion of linoleic acid in plasma phospholipids (Table 4) . FO consumption caused a significant (P, 0·05) increase in the proportion of EPA in plasma phospholipids (Table 4 ). The observed increases in EPA content (approximately 115, 140 and 230 % in the low-, mediumand high-FO groups respectively) were linearly related to the amount of EPA supplied in the capsules (P¼ 0·01 for the relationship between change in EPA from baseline to weeks 12 and EPA intake from capsules). However, the proportion of EPA in plasma phospholipids was not different among the groups receiving different doses of FO at 12 weeks of treatment (Table 4) . FO consumption caused a significant (P, 0·05) increase in the proportion of DHA in plasma phospholipids (Table 4) . Although the increase was greater in the medium-and high-FO groups (100 and 125 % respectively) than in the low-FO group (45 %), at 12 weeks of treatment there were no differences in the proportion of DHA in plasma phospholipids among the groups receiving the three different doses of FO (Table 4) .
Peripheral blood mononuclear cells subsets
The proportions of lymphocytes as T lymphocytes, B lymphocytes or natural killer cells were not different among the treatment groups at baseline and were not significantly affected by the treatments (Table 5) . Likewise, the proportions of T lymphocytes as helper or cytotoxic cells were not different among the treatment groups at baseline, and were not affected by the treatments (Table 5) 
Cytokine production by peripheral blood mononuclear cells
The production of TNF-a and IL-1b by PBMC stimulated with LPS (15 mg/ml) and the production of IL-2, IL-4, IFNg and IL-10 by PBMC stimulated with ConA (25 mg/ml) did not differ among the treatment groups at baseline or at the end of supplementation and did not differ between time points within any treatment group (Tables 6 and 7) . However, production of IL-6 was decreased after 12 weeks in the medium-and high-FO groups, such that it was significantly (P, 0·05) lower than at baseline and significantly (P, 0·05) lower than that observed in the placebo group (Table 6 ). In the medium-FO group, the range of the decrease was 19-90 % with a mean decrease of 65 %. In the high-FO group, the range of the decrease was 15-61 % with a mean decrease of 40 %.
Lymphocyte proliferation
For all subjects, peak incorporation of thymidine occurred at a ConA concentration of 25 mg/ml. Thymidine incorporation in response to each concentration of ConA used did not differ among treatment groups at baseline or at the end of supplementation (results for 25 mg/ml ConA are shown in Table 7 ). However, thymidine incorporation decreased with time in all groups, such that it was less at the end of supplementation than at baseline in each group (Table 7) . Placebo  0  22·9  0·8  8·2  0·5  1·1  0·2  3·8  0·3  12  24·4  1·1  8·4  0·5  0·8  0·3  4·1  0·3  ALNA  0  23·6  0·5  8·6  0·4  1·0  0·5  3·9  0·5  12  23·3  0·4  8·0  0·3  1·6* †  0·3  4·0  0·4  Low-FO  0  24·4  1·1  9·2  0·5  0·7  0·2  3·7  0·3  12  23·4  1·3 Tables 1 and 2 , and p. 680.
Discussion
A number of studies in healthy human volunteers have reported that long-chain n-3 PUFA diminish mononuclear cell functions (Endres et al. 1989 (Endres et al. , 1993 Meydani et al. 1991b Meydani et al. , 1993 Molvig et al. 1991; Virella et al. 1991; Gallai et al. 1993; Caughey et al. 1996; Kelley et al. 1998 Kelley et al. , 1999 , suggesting that FO could compromise host defence. However, since these studies have used FO providing 2·4-6·0 g (EPA þ DHA)/d, they represent a 10-to 30-fold increase in EPA þ DHA consumption. Likewise, some studies in healthy human subjects that examined the effects of ALNA on mononuclear cell functions used 14 or 18 g ALNA/d (Kelley et al. 1991; Caughey et al. 1996) , which is at least 7-fold greater than the habitual intake of this fatty acid (British Nutrition Foundation, 1999) . Relatively little is known about the effects of more modest consumption of n-3 PUFA on human mononuclear cell functions, or about dose -response relationships.
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n-3 Fatty acids and mononuclear cell functionn-3 Fatty acids and mononuclear cell functionstudies, which suggest that substantial increases in ALNA intake are required before this fatty acid appears in plasma phospholipids (Mantzioris et al. 1994 (Mantzioris et al. , 1995 Li et al. 1999; Thies et al. 2001c; Finnegan et al. 2003) . The observed increase in the proportion of EPA in plasma phospholipids following chronic ALNA consumption has been reported previously (Sanders & Younger, 1981; Mantzioris et al. 1994; Li et al. 1999; Finnegan et al. 2003) . The current study found that the proportion of DHA was not increased after increased consumption of ALNA, suggesting that the EPA formed from ALNA is not further desaturated and elongated. The lack of change in the DHA content of plasma phospholipids after increased ALNA consumption is consistent with earlier studies (Sanders & Younger, 1981; Li et al. 1999; Thies et al. 2001c; Finnegan et al. 2003) . Despite the increase in ALNA intake and the altered plasma phospholipid EPA content, there was no change in lymphocyte proliferation or production of cytokines by monocytes and lymphocytes in the ALNA group. This in is contrast with studies using high doses of ALNA, in which decreased lymphocyte proliferation in response to ConA (Kelley et al. 1991) and decreased production of TNF-a and IL-1b by LPS-stimulated monocytes (Caughey et al. 1996) was reported. However, a recent study demonstrated that increasing ALNA intake by about 2 g/d did not affect lymphocyte proliferation or the production of a range of cytokines by monocytes and lymphocytes (Thies et al. 2001a,b) . The current study extends these earlier reports by demonstrating absence of effects of a higher ALNA intake on mononuclear cell functions. Furthermore, increasing ALNA intake by about 4 g/d did not influence neutrophil chemotaxis or superoxide production (Healy et al. 2000) . Taken together, these studies demonstrate that increasing ALNA intake to 4 g/d is unlikely to have deleterious immunological effects. This is important, because there are recommendations to increase ALNA intake because of its potential benefits to human health. However, it is clear from earlier studies (Kelley et al. 1991; Caughey et al. 1996 ) that large increases in ALNA intake (^14 g/d) may not be immunologically desirable.
Subjects in the three FO groups increased their EPAþ DHA intakes by approximately 220, 440 and 950 % respectively. This resulted in significant (P, 0·05) increases in the EPA and DHA content of plasma phospholipids. This increase in EPA and DHA content was paralleled by a decrease in the content of ARA in plasma phospholipids, which occurred despite the higher ARA intake in the groups receiving the two higher doses of FO. Qualitatively, these changes in EPA, DHA and ARA content of plasma phospholipids are consistent with earlier literature (Meydani et al. 1991b; Gibney & Hunter, 1993; Yaqoob et al. 2000; Thies et al. 2001c) . The increase in EPA and DHA content was dose-dependently related to the amount of EPA or DHA provided in the capsules. Thus, the present study shows that n-3 PUFA of both marine and plant origin can modulate the content of EPA in plasma phospholipids. However, the degree of enrichment in EPA resulting from an increase in ALNA intake of 3·5 g/d is less than that resulting from an increase in EPA intake of 0·27 g/d. Furthermore, while FO increases plasma phospholipid DHA content, this is not influenced by an increase in ALNA intake of 3·5 g/d.
Increasing the intake of EPA + DHA did not affect mononuclear cell proportions, lymphocyte proliferation in response to several concentrations of ConA, the production of TNF-a and IL-1b by monocytes stimulated with LPS, or the production of a range of cytokines by lymphocytes stimulated with ConA. These findings appear to contrast with previous studies (Endres et al. 1989 (Endres et al. , 1993 Meydani et al. 1991b Meydani et al. , 1993 Molvig et al. 1991; Virella et al. 1991; Gallai et al. 1993; Caughey et al. 1996; Kelley et al. 1998 Kelley et al. , 1999 . However, the previous studies used greater amounts of EPA + DHA (2·4 -6·0 g/d) than used here. Some other studies using low amounts of EPA + DHA (0·55 -1·60 g/d) report no effects on the production of TNF-a and IL-1b by monocytes stimulated with LPS (Molvig et al. 1991; Cooper et al. 1993; Schmidt et al. 1996; Thies et al. 2001a) , or on the production of IL-2 and IFN-g by lymphocytes stimulated with ConA Thies et al. 2001b) . Taken together, Tables 1 and 2 , and p. 680.
these findings suggest that the dose of EPA + DHA is important, and that in the current study even the highest dose used was insufficient to influence these mononuclear cell responses. However, two studies report that 1·2 g (EPA + DHA)/d for 12 or 24 weeks resulted in a significant reduction in proliferation of lymphocytes Thies et al. 2001b) . There are three possible explanations for this apparent contradiction. The first is age: in the current study the subjects were young (, 39 years), whereas in the earlier studies Thies et al. 2001b ) subjects were elderly (mean age 65 years). It is possible that immune cells of older subjects are more sensitive to the effects of n-3 PUFA. This is supported by observations of Meydani et al. (1991b) , studying young and older women: 2·4 g (EPA + DHA)/d significantly decreased proliferation of lymphocytes from the older women, whereas there was no effect on those from the younger women. Thus, n-3 PUFA might have different immunological potencies according to age. The second factor that might contribute to contradictory effects regarding FO and lymphocyte proliferation is lipid peroxidation. Lipid peroxides inhibit lymphocyte proliferation (Begin, 1987; Madhavi et al. 1994) and might be part of the mechanism by which high intakes of n-3 PUFA impair this process (Kramer et al. 1991) . In the study of Meydani et al. (1991b) mentioned previously, 2·4 g (EPA + DHA)/d significantly elevated plasma TBARS concentration in the older, but not the younger, women (Meydani et al. 1991a ). In the current study, subjects consumed an extra 9 mg a-tocopherol/d during supplementation, increasing their habitual intake by about 100 %. This resulted in an increase in plasma a-tocopherol concentration in all subjects (by approximately 30 %) and there was no change in plasma TBARS concentration, indicating that the increased intake of PUFA had not increased lipid peroxidation. Thus, absence of increased lipid peroxidation in subjects in the current study may explain the lack of effect of n-3 PUFA on lymphocyte proliferation. Some earlier studies reporting an inhibitory effect of FO on mononuclear cell functions, such as lymphocyte proliferation, may not have provided sufficient a-tocopherol to prevent lipid peroxidation. The third factor that might contribute to contradictory effects regarding FO and lymphocyte proliferation is the precise nature of the n-3 PUFA used. In the current study, the FO was rich in DHA, so that subjects received a much higher amount of DHA than EPA. In the studies of Meydani et al. (1993) and Thies et al. (2001b) , the FO used was rich in EPA. Thus, the reason that there was no effect of lymphocyte proliferation in the current study may be that EPA is a more effective inhibitor of proliferation than DHA, and that the intake of EPA was insufficient to induce an effect. There is support for the idea that DHA is less inhibitory than EPA: in a study of elderly subjects, 0·75 g DHA/d did not affect lymphocyte proliferation, whereas FO providing 0·72 g EPA + 0·28 g DHA/d was inhibitory (Thies et al. 2001b) . Future studies should seek to discriminate between the effects of EPA and DHA on immune and inflammatory functions, and to identify whether the EPA: DHA ratio in FO is important in determining its biological effects.
The one significant effect on mononuclear cell responses observed in the current study was the reduction in IL-6 production after supplementation with the two higher doses of FO. An earlier study reported no effect of 0·55 g (EPA + DHA)/d on IL-6 production by LPS-stimulated monocytes (Schmidt et al. 1996) . Meydani et al. (1991b) reported 60 and 30 % decreases in IL-6 production by ConA-stimulated PBMC from older and younger women respectively, after 2·4 g (EPA + DHA)/d. In elderly subjects, 1·2 g (EPA + DHA)/d was reported to decrease IL-6 production by ConA-stimulated PBMC by 35 % . The current study is in general agreement with these earlier studies, in that it demonstrates no significant effect of 0·44 g (EPA + DHA)/d and a significant (P, 0·05) effect of 0·94 and 1·90 g (EPA + DHA)/d. However, the current study extends these earlier studies by identifying that the threshold dose at which n-3 PUFA are able to significantly (P, 0·05) decrease IL-6 production is between 0·44 and 0·94 g (EPA + DHA)/d. Whether this effect is due to EPA or DHA is not immediately apparent. Nevertheless, the observation of a significant effect of FO on IL-6 production, but not on the production of other cytokines in response to either LPS or ConA, indicates that different components of the mononuclear cell response to stimulation have different sensitivities to increased supply of long-chain n-3 PUFA. This suggests that there may be subtle differences in the mechanism by which n-3 PUFA influence the production of different cytokines.
An excessive production of IL-6 has been noted in patients with sepsis, burns and trauma (Pape et al. 2000; Spittler et al. 2000) and in chronic inflammatory diseases such as rheumatoid arthritis (Dasgupta et al. 1992) . The ability of a modest intake of FO to decrease IL-6 production by PBMC suggests that administration of longchain n-3 PUFA might be a useful therapeutic strategy in these conditions (see Calder, 2002 ).
An unexpected finding in the current study was the reduction in lymphocyte proliferation in all groups at 12 weeks compared with baseline. This may be due to seasonal factors, which have been shown to exert a particularly strong effect on T lymphocyte proliferation. For example, ConA-stimulated proliferation of PBMC from male rhesus monkeys housed under natural lighting conditions was about 80 % less in summer than in winter (Mann et al. 2000) , an effect also observed for lymphocytes from mice (for review, see Nelson & Demas, 1996) .
In summary, the current study suggests that modest levels of either plant-or marine-derived n-3 PUFA do not influence circulating mononuclear cell numbers and do not impair most functional responses of these cells over a 12-week period. Thus, it appears that consumption of n-3 PUFA could be increased in accordance with recommendations, without inducing adverse effects on these components of the immune system and thus on the ability of individuals to mount a successful immune response. However, the current study was conducted in male subjects aged 18 -39 years and the findings should not be extrapolated to other groups such as the elderly, infants or pregnant women. It will be important to conduct similar dose response studies of the effect of n-3 PUFA on immune function in groups other than that studied here.
